Amgen Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:45PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon, everybody. I'm Chris Schott from JPMorgan, and it's my pleasure to be introducing Amgen today. From the company, we have the Chairman and CEO, Bob Bradway. Obviously, a very eventful year for the company in 2022, and look forward to hearing from Bob as we think about the story going forward. So with that, I'll turn it over.

Robert A. Bradway - Amgen Inc. - Chairman, CEO & President

Okay. Thank you, and thank you for your interest in Amgen. We feel we've delivered well in the past and that we're well positioned to deliver in the future. Now, I know that many of you are very familiar with Amgen, but there are a few who are joining this event that are a little bit less familiar with our company. So I thought I might just take a couple of moments and very quickly orient those of you who are new to Amgen, to our company.

I would start by pointing out that these are our 26, 27 brands. What they have in common is that they address serious illnesses and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot